Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06943872 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

StatusRecruiting
PhasePhase 3
Started2025-06-11
View on ClinicalTrials.gov ↗

Amendment history

2026-08-20
Study Status, Contacts/Locations v29
Study sitesdetails revised at 1 of 195 sites
2026-08-06
Study Status, Contacts/Locations v28
Trial sites expanded: 192 → 195 locations
2026-07-27
Study Status, Contacts/Locations v27
Trial sites expanded: 187 → 192 locations
2026-07-07
Study Status, Contacts/Locations v26
Trial sites expanded: 173 → 187 locations
2026-06-03
Study Status, Contacts/Locations v25
Study sites171→173
2026-05-22
Study Status, Contacts/Locations v24
Study sites170→171
2026-05-08
Study Status, Contacts/Locations v23
Trial sites expanded: 167 → 170 locations
2026-04-21
Study Status, Contacts/Locations v22
Trial sites expanded: 164 → 167 locations
2026-04-14
Study Status, Contacts/Locations v21
Trial sites expanded: 155 → 164 locations
2026-03-17
Study Status, Contacts/Locations v20
Study sites149→155
2026-03-03
Study Status, Sponsor/Collaborators, Study Description, Contacts/Locations, IPDSharing v19
Study sites141→149
Lead sponsorBeiGene→BeOne Medicines
Study description+209 characters
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
2026-02-19
Study Status, Contacts/Locations v18
Study sites129→141
2026-02-12
Study Status, Contacts/Locations v17
Study sites108→129
2026-01-23
Study Status, Contacts/Locations v16
Study sites88→108
2025-12-22
Study Status, Contacts/Locations v15
Study sites72→88
2025-12-15
Study Status, Contacts/Locations v14
Study sites60→72
2025-11-19
Study Status, Contacts/Locations v13
Study sites56→60
2025-11-07
Study Status, Contacts/Locations v12
Study sites50→56
2025-11-04
Study Status v11
Completion date2032-12-31→2031-12
2025-10-23
Study Identification, Study Status, Contacts/Locations v10
Study sites178→50
2025-09-19
Study Status, Contacts/Locations v9
Study sites177→178
2025-09-11
Study Status, Contacts/Locations v8
Study sites176→177
2025-08-19
Study Status, Contacts/Locations v7
Study sites157→176
2025-08-11
Study Status, Contacts/Locations v6
Study sites156→157
2025-07-22
Study Status, Contacts/Locations v5
Study sites156 entries, revised
LandeskrankenhausMedizinische UniversitaetsklinikenUniversitatsklinik Innsbruck
2025-07-10
Study Status, Contacts/Locations v4
Study sites155→156
2025-06-23
Study Status, Contacts/Locations v3
Study sites154→155
2025-06-12
Study Status v2
Start dateestimated 2025-06→confirmed 2025-06-11
2025-06-10
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start date2025-05→2025-06
Study sites0→154
2025-04-17
Original filing
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.
Trial Details
NCT Number NCT06943872
Lead Sponsor BeOne Medicines
Collaborators: German CLL Study Group
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment 630 participants
Start Date 2025-06-11
Primary Completion 2029-09-30 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-09-28